A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer’s Disease (BenfoTeam)

The BenfoTeam clinical research trial is based on evidence from decades of research on the role of thiamine in Alzheimer’s disease (AD). BenfoTeam scientists have found that thiamine (vitamin B1) does not enter the brains of people with early Alzheimer’s disease despite having a sufficient supply of thiamine in their blood. Fortunately, there is also evidence that this problem with thiamine in the brain may be overcome by boosting the amount of thiamine in the blood far above usual levels. Benfotiamine, a lab-made version of thiamine, is the drug being tested in the BenfoTeam trial. BenfoTeam tests if increasing thiamine in the blood slows cognitive decline in people with early Alzheimer’s disease, including Mild Cognitive Impairment (MCI) and mild dementia. An earlier trial of benfotiamine showed encouraging results.

For more information, please see https://clinicaltrials.gov/study/NCT06223360.

Study Length

Disorder/Condition

Inclusion Criteria

The study is open to both male and female subjects, aged 50-89 years.

Study Description (brief)

A new approach in early Alzheimer’s disease research, including Mild Cognitive Impairment and early dementia

Study Contact

Antero Sarreal at 845-398-6532 or [email protected].

Study Location